Document is current

Any future updates will be listed below

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

Crossref DOI link: https://doi.org/10.1038/s41409-018-0261-y

Published Online: 2018-06-15

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark